Welcome to Flow Pharma Inc.

Page Loading...

Menu

FLOVID-20

Treatment for new COVID-19 patients. Administered by simple inhaler.

Mutations are rising. FLOVID-20 is predicted to work against all known variants.

Under Development, FDA Approval Required


The FlowVax Platform

A simple immunotherapy platform that creates medicines for a wide range of cancers and viral diseases.

FlowVax targets diseases with tailor-made precision medicines that are designed to maximize benefits and minimize side effects.


Stable Dry Powder

Multiple Delivery Pathways

  • For Virus – inhalation, intramuscular

  • For Cancer – intranodal, intramuscular

Quick manufacturing ramp-up. Multi-million dose weekly production.


blob-1
blob-2
Our Mission

Flow Pharma engineers and manufactures state-of-the-art biomedicines.

Our unique patented delivery systems and biotechnology are ideally suited for curative intervention in COVID-19, Ebola, and treatment-resistant cancers.



FLOVID-20

COVID-19

A prophylactic needle-free nebulizer treatment to prevent COVID-19 in both virus-exposed and healthy patient populations. A unique targeted T-Cell immunotherapy biomedicine designed to help cure and prevent COVID-19.

FlowVax Ebola & Marburg

Ebola, Marburg, Nebulizer

Marburg is an Ebola-like virus weaponized by hostile forces. By relying on T-cells rather than antibodies, we provide long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola and Marburg virus nucleocapsid proteins.

FlowVax BreastCA

Cancer

A revolutionary approach to breast cancer that utilizes T-cell biomedicines to provide highly efficacious therapy.

FlowVax HPV

Cancer, HPV

FlowVax-HPV is under development as a targeted T-cell immunotherapy for HPV induced squamous cell carcinomas of the head, neck, and cervix.